On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...